research use only

Thymidine DNA/RNA Synthesis chemical

Name: Thymidine
Brand: Selleck Chemicals
SKU: S4803
Availability: InStock
Rating: 5 (11 reviews)

Cat.No.S4803

Thymidine is a pyrimidine nucleoside that is composed of the pyrimidine base thymine attached to the sugar deoxyribose. As a constituent of DNA, thymidine pairs with adenine in the DNA double helix.

Chemical Structure

Molecular Weight: 242.23

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	HDAC Topoisomerase PPAR PARP Sirtuin ATM/ATR Casein Kinase eIF MDM2/MDMX DNA-PK DHFR Nucleoside Analog/Antimetabolite DNA alkylator Telomerase Thymidylate Synthase CRISPR/Cas9 RAD51 BMI-1 LIM kinase RNR Alkylating Agent NUDIX High-mobility Group OGG1 MTH1 G-quadruplex SMN FENs WRN Pax
Related Products	CX-5461 (Pidnarulex) SCR7 Favipiravir (T-705) RK-33 Carmofur Triapine (3-AP) B02 BMH-21 YK-4-279 Bergapten Tegafur (FT-207) Azaguanine-8 Halofuginone Adenine HCl Mizoribine Cyclocytidine HCl APX-3330 Nedaplatin 6-Thio-dG Flupirtine maleate JH-RE-06 Pritelivir (BAY 57-1293) TK216 Amenamevir Madrasin Tubercidin BC-LI-0186 CRT0044876 PFM01 Adenine

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Vero	Antiviral assay			Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay, IC50 = 0.0003 μM.	10464017
HepG2.2.15	Antiviral assay			Antiviral activity against HBV in HepG2.2.15 cells assessed as decrease in extracellular viral DNA level by RT-PCR, EC50 = 0.3 μM.	17404006
HL-60	Function assay			The compound was tested for [3H]TdR incorporation into DNA in HL-60 cells, ID50 = 0.61 μM.	2840503
Vero	Function assay			Compound was evaluated for Kinetic constant for cellular thymidine kinase in Vero cells, Km = 0.81 μM.	3033244
HEL	Antiviral assay		3 days	Antiviral activity against Human adenovirus 2 infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by microscopic method, EC50 = 22 μM.	30286952
ONS	Function assay	10 uM	24 hrs	Induction of phenotypic perturbation in human ONS cells assessed as decrease in EEA1-associated early endosomes level in at 10 uM after 24 hrs by EEA1 staining based assay relative to control	26883470
ONS	Function assay	10 uM	24 hrs	Induction of phenotypic perturbation in human ONS cells assessed as decrease in autophagy markers level in at 10 uM after 24 hrs relative to control	26883470
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	242.23	Formula	C₁₀H₁₄N₂O₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	50-89-5	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	NSC 21548, Deoxythymidine, 2'-Deoxythymidine, 5-Methyldeoxyuridine, DThyd			Smiles	CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O

Solubility

In vitro
Batch:

DMSO : 48 mg/mL (198.15 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 48 mg/mL

Ethanol : 9 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	Thymidine (NSC 21548), a pyrimidine nucleoside that is composed of the pyrimidine base thymine attached to the sugar deoxyribose, pairs with adenine when DNA synthesis.^[1]
References	[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733264/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01199250	Not yet recruiting	Lynch Syndrome\|Recurrent Uterine Corpus Carcinoma\|Stage I Uterine Corpus Cancer\|Stage II Uterine Corpus Cancer\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	January 2100	--
NCT04598516	Withdrawn	Acute Kidney Injury (Nontraumatic)\|Contrast-induced Nephropathy\|Renal Insufficiency	Maastricht University Medical Center	November 1 2097	--
NCT05454306	Suspended	Clavicle Fracture	University of Minnesota	January 9 2028	Not Applicable
NCT04795856	Not yet recruiting	Mitral Valve Regurgitation	University of Alabama at Birmingham	June 18 2027	Early Phase 1
NCT06359262	Not yet recruiting	Mental Health Wellness 1	Karolinska Institutet	January 1 2027	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):